RxSight manufactures and sells the Light Adjustable Lens system, the first and only FDA-approved adjustable intraocular lens for use in cataract surgery. After implantation, physicians use a non-invasive office-based Light Delivery Device to apply ultraviolet light patterns that precisely reshape the photosensitive lens material, allowing customization of the patient’s vision once the eye has healed. This post-operative adjustability enables outcomes based on actual refractive results and patient feedback rather than solely on pre-operative measurements.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 37.9 | — | -8.2 | — |
| Q2 2025 | 33.6 | — | -11.8 | — |
| Q3 2025 | 30.3 | — | -9.8 | — |
| Q4 2025 | 32.6 | — | -9.2 | — |
| Q1 2026 | 30.9 | -18.5% | -15.9 | — |
| Q2 2026 | 33.7 | 0.3% | -12.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: TriSalus Life Sciences, Inc. (TLSI), Matrix Service Company (MTRX), Bitcoin Infrastructure Acquisition Corp Ltd. (BIXI), Art Technology Acquisition Corp. (ARTC), Orchestra BioMed Holdings, Inc. (OBIO), Corvex, Inc. (MOVE)